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N-acetyl-L-cysteine (NAC)Huntington's disease (HD) is an autosomal dominant neurological disorder that is induced by a CAG trinucleotide
expansion in exon 1 of theHuntingtin (HTT) gene.We previously reported that the abnormal activation of an im-
portant energy sensor, AMP-activated protein kinase α1 (AMPK-α1), occurs in the brains of mice and patients
with HD, which suggests that this abnormal activation may contribute to neuronal degeneration in HD. In the
present study, we demonstrated that the elevated oxidative stress that was evoked by a polyQ-expandedmutant
HTT (mHTT) caused the abnormal activation of AMPK-α1 and, subsequently, resulted in neurotoxicity in a
striatal progenitor cell line (STHdhQ109) and in the striatum of a transgenic mouse model of HD (R6/2). The sys-
tematic administration of an antioxidant (N-acetyl-cysteine, NAC) to R6/2 mice suppressed the activation of
AMPK-α1, reduced neuronal toxicity, which was assessed by the activation of caspases, increased neuronal den-
sity, ameliorated ventricle enlargement, and improved motor dysfunction. This beneﬁcial effect of NAC in vivo
appears to be direct because NAC also reduced the activation of AMPK-α1 and the death of STHdhQ109 cells
upon elevated oxidative stress. Moreover, the activation of AMPK enhanced the level of oxidative stress in
STHdhQ109 cells, in primary neurons of R6/2 mice, and in the striatum of two different HD mouse models (R6/2
and Hdh150Q/+), whereas the inhibition of AMPK reduced the level of oxidative stress. Collectively, our ﬁndings
suggest that positive feedback regulation between the elevated oxidative stress and the activation of AMPK-α1
contributes to the progression of HD.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is an autosomal dominant neurodegener-
ative disease that is caused by a CAG trinucleotide expansion in exon 1
of theHuntingtin (HTT) gene,which is located on chromosome 4 (4p63).
When the number of CAG repeats is higher than 36, the resultant polyQ-
expandedmutant HTT (mHTT) protein is prone to aggregate formation,
compromises the activity of proteasomes, dysregulates the transcrip-
tion machinery (e.g., the suppression of the expression of BDNF andA carboxylase; AD, Alzheimer's
MPK, AMP-activated protein ki-
langiectasia mutated; CaMKII,
lmodulin-dependent protein ki-
Htt, Huntingtin; mHtt, mutant
ing; NES, nuclear export signal;
isease; PGC-1α, peroxisome
PKA, cAMP-dependent kinase;
R, ventricle-to-brain ratio; WT,
ces, Academia Sinica, Nankang,
27829143.
rn).PGC-1α), impairs synaptic functions, elevates oxidative stress, degener-
ates axons, and eventually leads to neuronal atrophy and loss [1–5].
Elevated oxidative stress has been widely observed in neurodegen-
erative diseases, including HD, and is believed to play a critical role in
HD pathogenesis. Speciﬁcally, high oxidative stress in HD is associated
with proteasome malfunction, which acerbates aggregate formation,
somatic CAG expansion in neurons [6], cell death [7], and the deﬁciency
of the mitochondrial complex IV. Furthermore, mHTT inclusions appear
to be the production source of reactive oxygen species (ROS) because a
signiﬁcant amount of oxidized proteins was detected in partially puri-
ﬁed mHTT aggregates [8]. It is not surprising to ﬁnd that the onset and
progression of HD correlate well with the level of ROS in both mice
and patients with HD [9–11]. Several antioxidants (such as green tea,
coenzyme Q10, creatine, and BN82451) were used as treatment in ani-
mal models of HD and produced beneﬁcial effects, including increased
survival, improvedmotor functions, reduced brain atrophy and ventric-
ular enlargement, and fewer intranuclear inclusions [12–14].
The AMP-activated protein kinase (AMPK) is a key energy sensor,
which is important in maintaining energy homeostasis [15]. AMPK
consists of three subunits (α, β, and γ) and is activated via the
phosphorylation of the threonine residue 172 (Thr172) of theα subunit.
Several kinases are known to regulate the activity of AMPK, including
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kinase B1 (LKB1), TGF-β-activated kinase 1 (TAK1), cAMP-dependent
kinase (PKA), ataxia telangiectasia mutated kinase (ATM), and
Ca2+/calmodulin-dependent protein kinase II (CaMKII) [16–21]. In the
brain, AMPK plays a critical role in the regulation of food intake in hypo-
thalamic neurons [22]. The importance of AMPK in neurodegenerative
diseases (including HD, Alzheimer's disease, Parkinson's disease,
and amyotrophic lateral sclerosis) has also been actively investigated
[21,23–25].
The interplays between AMPK and ROS are complex. In some cells,
AMPK is a downstream target of ROS. For example, oxidative stress se-
lectively activates AMPK-α1, which stimulates glucose transport in
skeletal muscle [26] and protects a rat dental pulp cell line (RPC-C2A)
from damage that was caused by ROS [27]. However, AMPKwas report-
ed to exert anti-apoptotic effects through the suppression of ROS in
other types of cells [28]. Speciﬁcally, the activation of AMPK was
shown to reduce oxidative stress by modulating the level or activity of
NAD(P)H oxidase, inducible nitric oxide synthase, cyclooxygenase-2,
manganese superoxide dismutase, or uncoupling protein 2 [29]. We
previously reported that, in striatal neurons of HDmice, AMPK-α1 is ab-
normally activated by mHTT via a CaMKII-dependent pathway and ex-
erts a detrimental effect on neuronal survival via the suppression of
the functions of two pro-survival proteins (i.e., CREB, Bcl2) [21]. The
role of the interaction between AMPK-α1 and ROS in HD pathogenesis
has not been previously characterized. In the present study, we demon-
strated that elevated oxidative stress in the striatum is an important
upstreampositive regulator of AMPK-α1, which promotesmHTT aggre-
gation and enhances the mHTT-mediated neuronal atrophy. Our data
also suggest that positive feedback regulation between the activation
of AMPK-α1 and the formation of ROS exists in striatal progenitor cell
lines and primary neurons. Most importantly, chronic treatment with
a ROS scavenger (N-acetyl-L-cysteine, NAC) ameliorated the detrimen-
tal effects of AMPK and protected striatal neurons fromneuronal degen-
eration in HD.
2. Materials and methods
2.1. Animals and AICAR administration
R6/2mice (B6CBA-Tg(HDexon1)62Gpb/1J)were originally obtained
from Jackson Laboratories (Bar Harbor, ME, USA) [30]. The number of
CAG repeats of R6/2 mice that were used in this study was 222 ± 5
(mean ± SEM). Animals were maintained on a 12-h light/dark
cycle at the Institute of Biomedical Sciences Animal Care Facility. To ac-
tivate AMPK in vivo, mice were subcutaneously administered AICAR
(3 μg/animal/day) or saline into the striatum for 1 day via osmotic
minipumps (ALZET, Cupertino, CA, USA). The AP and ML coordinates
were 0.5 and ±2 mm relative to the bregma, respectively. The dorso-
ventral coordinates were −3, −2.7, and −2.4 mm relative to the
bregma.
The knock-in Hdh150Q mice (B6.129P2-Hdhtm2Detl/J) were initially
obtained from Jackson Laboratories [31]. These mice harbor either
one or two copies of mutant HTT containing 150 glutamine repeats
(designated Hdh150Q/+ and Hdh150Q/150Q, respectively).
All animal experimental protocols were approved by the Academia
Sinica Institutional Animal Care and Utilization Committee (Taipei,
Taiwan).
2.2. Cell cultures and primary neuronal cultures
The striatal progenitor STHdhQ7 and STHdhQ109 cell lines,whichwere
developed fromwild-typemice andHdh150Q knock-in mice, respective-
ly, were generous gifts from Dr. E. Cattaneo (University of Milano, Italy)
[32]. These cells were maintained in an incubation chamber, which was
gassed with 5% CO2 at 33 °C. Cells were transfected using Lipofectamine2000 (Invitrogen Corporation, Carlsbad, CA, USA) for 48 h according to
the manufacturer's protocol.
Primary neuronal cultures were isolated from R6/2 mice and their
littermate controls at embryonic day 18 (E18). Brieﬂy, embryo cortices,
hippocampus, and striatumwere dissected and incubated in 0.05% tryp-
sin-EDTA (Invitrogen, Grand Island, NY, USA) at 37 °C for 10min. Tryp-
sin activity was neutralizedwith fetal bovine serum (FBS). The digested
tissue mixture was dissociated by gentle pipetting in modiﬁed Eagle's
medium (MEM) containing 5% FBS, 1% insulin–transferrin–selenium
supplement, 5% horse serum, 0.6% glucose, and 0.5 mM L-glutamine.
Cells were plated onto poly-L-lysine-coated cover slips. After a 3 h-incu-
bation, MEM was replaced with Neurobasal medium supplemented
with 2% B27 (Invitrogen, San Diego, CA, USA), 12.5 mM glutamate,
and 0.5 mM L-glutamine. Cells weremaintained in an incubation cham-
ber supplied with 5% CO2/95% air at 37 °C.
2.3. Measurement of ROS
Cellular ROS contents were measured using the ﬂuorescent probe
2,7-dichlorodihydroﬂuorescein diacetate (H2DCFDA; Molecular Probes,
Inc., Eugene, Oregon, USA). Brieﬂy, cells were incubated with H2DCFDA
(50 μM) for 30 min at 33 °C in normal culture medium. Cells were
washed 3 times in Locke's buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM
CaCl2, 1 mMMgCl2, 3.6 mM NaHCO3, 15 mMHepes, and 10 mM D-glu-
cose, pH 7.3), lysed in Tris-EDTA buffer (10 mM Tris–HCl, 1 mM
disodium EDTA, pH 8.0) containing 0.2% Triton X-100 for 10 min, and
centrifuged at 15,000 g for 5 min at 4 °C. The cytoplasmic fraction was
collected for the quantiﬁcation of ﬂuorescence intensity (Excitation/
Emission: 488 nm/510 nm) by a ﬂuorescence plate reader (Fluoroskan
Ascent; Thermo Electron Corporation, Woburn, MA, USA).
To detect ROS in primary neurons, cells were incubated with the
CellROX™ Deep Red Reagent (5 μM; Molecular Probes, Inc., Eugene,
Oregon, USA) and Hoechst 33342 (1 μg/mL) for 30 min at 33 °C in nor-
mal culture medium. Cells were washed three times with PBS. Images
were acquired using a laser confocal microscope (CellROX™ Deep Red
Reagent: excitation/emission, 640 nm/665 nm; LSM780, Carl Zeiss
MicroImaging).
The ROS level in brain tissues was measured using the OxiSelect™
In Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc., San Diego, CA, USA). Brief-
ly, tissue lysates (10 μL) were incubated with the catalyst (10 μL) in a
96-well plate for 5 min at room temperature (RT), followed by the
addition of DCFH solution (100 μL) for a 30-min incubation at RT in
the dark. Fluorescence was detected using a ﬂuorescence plate reader
(excitation/emission, 480 nm/530 nm).
To measure ROS in the brain, mice were intravenously injected with
dihydroethidium (DHE, Invitrogen, Carlsbad, CA, USA; 0.5 mg per
mouse) the day before harvesting [33]. Brain tissues were harvested
to analyze ROS production using an IVIS spectrum imaging system
(IVIS 200; Xenogen, CA, USA) with a ﬂuorescence ﬁlter (Excitation:
500–550 nm, Emission: 575–650 nm). Data analyses were performed
using the software Living Image (Xenogen).
2.4. Constructs
The mouse AMPK-α1 was ampliﬁed from a mouse brain cDNA by
PCR and subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). The
preparation of the dominant positive and negative mutants of AMPK-
α1 (AMPK-α1-172T/D, AMPK-α1-172T/A, AMPK-α1-172T/D-NLS/NES:
YFP, AMPK-α1-172T/A-NLS:YFP) was described previously.
2.5. Cell death assays
STHdhQ7 and STHdhQ109 cell death was quantiﬁed by theMTT reduc-
tion assay and by a ﬂow cytometric analysis. For the MTT reduction
assay, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) was dissolved in dimethyl sulfoxide (DMSO) at 50 mg/ml as a
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in culturemediumwith 0.5 mg/mlMTT at 37 °C for 2 h. The cultureme-
diumwas then replaced with DMSO to dissolve the MTT formazan pre-
cipitates, which was followed by the measurement of the absorbance
at 570 nm using a microplate reader (OPTImax tunable plate reader,
Molecular Device, Sunnyvale, CA, USA).
Apoptotic analyses of STHdhQ7 and STHdhQ109 cells by ﬂow cytometry
were conducted by staining cells using propidium iodide (PI) and were
analyzed by a ﬂow cytometer (BD Biosciences, San Jose, CA, USA). Brieﬂy,
cells were rinsed with ice-cold phosphate-buffered saline (PBS) at the
end of drug treatment, ﬁxed with ethanol (70%) at−20 °C for 1 h, and
rehydratedusing ice-cold PBS. PI (50 μg/ml)was then added into cell sus-
pension to stain cells before subjecting them to the ﬂow cytometric anal-
ysis. Cells existing in the sub-G1phasewere considered apoptotic cells. At
least 10,000 gated cells were counted for each sample. The data were an-
alyzed using the CellQuest™ software (BDBiosciences, San Jose, CA, USA).
For in vivo cell death assays, the SR-FLIVO™ in vivo apoptosis assay
kit (Immunochemistry Technologies, LLC, Bloomington, MN, USA) was
employed [34]. In brief, SR-FLIVO™ was intravenously injected into
the lateral tail vein of eachmouse and allowed to circulate in the animal
for 60 min. Mouse brains were then perfused with 4% paraformalde-
hyde in 0.1M phosphate buffer (PB, pH 7.4) as described above. Coronal
serial sections (20 μm) were used to analyze the activation of caspases
by detecting the signal of SR-FLIVO™ using a laser confocal microscope
(LSM780)with excitation at 565 nmand emission at 600 nm. The quan-
titation of active caspases was analyzed by a MetaMorph imaging sys-
tem (Universal Imaging, Westchester, PA, USA).
2.6. SDS-polyacrylamide gel electrophoresis (PAGE) and western blotting
Cellular proteins were extracted in TNE buffer [50 mM Tris–HCl
(pH 7.4), 100 mM NaCl, 0.1 mM EDTA and 1% Triton X-100]. Proteins
were electrophoretically fractionated through 10% and 15% PAGE and
then electrotransferred onto PVDF membranes (Millipore, Bedford,
MA, USA) forWestern blot analyses. Dilutions of the primary antibodies
that were used in the present study are listed below: anti-phospho-
AMPKαT172 (1:1000, Cell Signaling Technology, Danvers, MA, USA),
anti-AMPK-α1 (1:1000, Abcam Cambridge, MA, USA), anti-phospho-
CaMKIIT286 (1:1000; Abcam), anti-CaMKII (1:1000; Abcam) and anti-
Actin (1:5000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Immunoreactive signals on Western blots were detected using an ECL
detection system (PerkinElmer Life and Analytical Sciences, Boston,
MA, USA).
2.7. Immunohistochemical staining
Immunohistochemical staining was performed as previously de-
scribed [21]. For brain sections, mice were ﬁxed by perfusion with 4%
paraformaldehyde in phosphate buffer (PB, 0.1 M sodium phosphate
pH 7.4). After perfusion, the brain tissues were removed and post-
ﬁxed with 4% paraformaldehyde/0.1 M PB overnight, immersed in 30%
sucrose in 0.1 M PB for several days, and frozen at−80 °C. The brain
sections (20 μm) were incubated with the desired primary antibodies
in PBS containing 5% normal goat serum at 4 °C overnight and were
then incubated with the corresponding secondary antibody for 2 h at
room temperature. Dilutions of the primary antibodies that were used
in the present study are listed below: anti-phospho-AMPKαT172
(1:100, Cell Signaling Technology, Danvers, MA, USA), anti-AMPKα1
(1:200, Cell Signaling Technology, Danvers, MA, USA), and anti-NeuN
(1:1000, NeuN, Millipore, Bedford, MA, USA). The nuclei were stained
with Hoechst 33258. The immunostaining pattern was visualized
using a laser confocal microscope (LSM780, Carl Zeiss MicroImaging).
The quantitation of immunoﬂuorescence signals in primary neurons
was performed on a laser confocalmicroscope using 40× oil-immersion
objective lenses (LSM780, Carl Zeiss MicroImaging) and analyzed using
the MetaMorph imaging system (Universal Imaging, Westchester, PA,USA). The ﬂuorochromes used in the present study were Alexa Fluor
405, Alexa Fluor 488, and Alexa Fluor 633. At least 50 cells from each an-
imal were counted and analyzed.
2.8. Micromagnetic resonance imaging (μMRI) analysis
Three-dimensional (3D) and whole-brain ventricle images of mice
were evaluated using a Bruker PharmaScan (7T) scanner (Madison,
WI, USA) as described previously [21]. The ventricle-to-brain ratio
(VBR) was calculated by dividing the value of the ventricle by that of
the entire brain.
2.9. Filter retardation assay
Brain tissues were suspended and homogenized in ice-cold TNE
buffer (50 mM Tris–HCl (pH 7.4), 100 mM NaCl, 0.1 mM EDTA and 1%
Triton X-100), mixed with 2% SDS. Samples were ﬁrst passed through
OE66 membrane ﬁlters (0.2 mm pore size; Whatman Schleicher and
Schuell, Middlesex, UK) in a slot-blot manifold (Bio-Rad, Irvine, CA,
USA). The membrane ﬁlters were blocked with 5% skim milk in TBST
and incubated overnight with an anti-Htt antibody (1:500; Millipore
Bioscience Research reagents, Temecula, CA, USA) at 4 °C, followed by
1 h incubation with the secondary antibody at room temperature. Im-
munoreactive signals were detected using an ECL detection system
and were recorded using Kodak XAR-5 ﬁlms.
2.10. Statistical analysis
Results were expressed as means ± SEM of triplicate samples. Each
experiment was repeated at least three times to conﬁrm the reproduc-
ibility of ﬁndings. Multiple groups were analyzed by one-way analysis
of variance (ANOVA) followed by a post hoc Student–Newman–Keuls
test. Differences were considered statistically signiﬁcant if the P value
was less than 0.05.
3. Results
3.1. Elevated oxidative stress in the brain of HD mice contributes to the ac-
tivation of AMPK-α1 in striatal neurons
AMPK is known to be regulated bymultiple upstream regulators.We
set out to determinewhether, in addition to the CaMKII-mediated path-
way, additional pathway(s) are involved in the activation of AMPK-α1
in striatal neurons of HD mice. We are particularly interested in oxida-
tive stress because it is a well-recognized contributor to HD pathogene-
sis [10,21]. In addition, CaMKII is known to mediate the actions of H2O2
in controlling signaling pathways, including ERK1/2, PKB, and IGF-1R,
in several cell types [35,36]. We ﬁrst showed that the overall ROS level
in the brain of a transgenic mouse model (R6/2, [30]) at the age
of 12 weeks was signiﬁcantly higher than that of wildtype mice
(Fig. 1A). To measure the ROS level in vivo, mice were intravenously
injected with a ﬂuorescent dye (dihydroethidium, DHE; 0.5 mg per
mouse) that is sensitive to superoxide production. The ROS level in
the brain wasmeasured using an in vivo IVIS imaging system. Our ﬁnd-
ings are consistent with several earlier studies, which showed higher
levels of ROS and/or more severe oxidative damage in brains of HD
mice [9]. Daily treatment with a ROS chelator (NAC, 250 mg/kg of
body weight, intraperitoneal injection) for 5 weeks from the age of
7 weeks markedly reduced the level of ROS in the brain (Fig. 1A).
Similar to what was found in R6/2 mice, the total ROS level in the
striatumof HDknock-inmice (Hdh150Q/150Q, [31]),whichwasmeasured
using an in vitro ROS assay, was higher than that of their littermate con-
trols (Fig. S1). We next determined the ROS level in striatal progenitor
cells, which were derived from wild-type mice (STHdhQ7) or knock-in
mice (STHdhQ109) that express HTT proteins harboring 7 and 109 copies
of the CAG repeat, respectively. The cellular level of ROS was assessed
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Fig. 1. Expression of polyQ-expandedmutant Huntingtin enhances the level of reactive oxygen species (ROS). (A) Mice were treated daily with an antioxidant (N-acetyl-L-cysteine, NAC;
250 mg/kg of body weight, intraperitoneal injection) or vehicle for 5 weeks from the age of 7 weeks. Wild-type mice [saline-treatedWTmice (n= 5), saline-treated R6/2 mice (n=6),
NAC-treatedWTmice (n= 5), and NAC-treated R6/2 mice (n= 6)] that were 12-weeks old were intravenously injected with a ROS sensor (dihydroethidium, DHE; 0.5 mg per mouse).
One day post-injection, brain tissueswere harvested to analyze the ROS levels using an IVIS® spectrum imaging system. The histograms show theﬂorescence intensity of DHE. The pseudo
colors represent photons/sec/cm2/Sr. The data are presented as themean± SEM. ap b 0.05, betweenWT and R6/2mice. bp b 0.05 vs. R6/2-saline-treatedmice. (B) Tomeasure cellular ROS
levels, cells were incubated with H2DCFDA (50 μM) for 30 min, followed by treatment with NAC (5mM) for 24 h. The ﬂuorescence intensity was quantiﬁed as described in the Materials
and methods section. The data are presented as the mean± SEM from three independent experiments. ap b 0.05 speciﬁc comparison between STHdhQ7 and STHdhQ109 cells. bp b 0.05 vs.
untreated cells. Sale bars are 10 μm.
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H2DCF-DA). When compared with STHdhQ7 cells, elevated ROS levels
were detected in the STHdhQ109 cells (Fig. 1B). As expected, NAC
(5 mM) signiﬁcantly reduced the ROS levels in STHdhQ109 cells.
To assess the inﬂuence of elevated ROS levels, we examined the ef-
fect of chronic treatment with NAC on disease progression in R6/2
mice. As shown in Fig. 2, chronic NAC treatment signiﬁcantly ameliorat-
ed the striatal atrophy of R6/2 mice, which was determined by in vivo
three-dimensional (3D)magnetic resonance imaging (MRI, Fig. 2A), en-
hanced the number of striatal neurons,whichwas assessed by immuno-
cytochemical staining (Fig. 2B), and reduced striatal toxicity, whichwas
determined by the level of activated caspases using an in vivo ﬂuores-
cent dye that recognizes activated caspase (SR-FLIVO™) (Fig. 2C). Con-
sistent with the improved neuronal survival in the striatum, NAC also
markedly enhanced the impaired motor function of R6/2 mice, which
was evaluated by rotarod performance (Fig. 2D), and reduced aggregate
formation in the striatum (Fig. 2E). These ﬁndings are consistent with
previous ﬁndings, which showed that antioxidant reagents produced
beneﬁcial effects on HD progression [12–14,37,38], and support the
hypothesis that elevated oxidative stress plays a key pathogenic role
in HD.To determinewhether AMPK is involved in the detrimental function
of ROS,we ﬁrst evaluatedwhether the reduction of ROS byNAC affected
the activation of AMPK in R6/2 mice. As shown in Fig. 3, chronic treat-
ment with NAC signiﬁcantly reduced the phosphorylation (activation)
level of AMPK at Thr172 (AMPKα-p172, Fig. 3A). We previously demon-
strated that AMPK regulated the expression of a survival factor, Bcl2
[39]. As shown in Fig. 3B, chronic treatment with NAC signiﬁcantly
enhanced the level of Bcl2 in R6/2 mice. Moreover, NAC also
reduced the expression of AMPKα-p172 and AMPK-α1 in striatal nuclei
of 12-week-old R6/2 mice (Fig. 3C, D). Given that the activation of
AMPK-α1 in striatal neurons leads to the enrichment of AMPK-α1 in
their nuclei [39], the above ﬁnding suggests that elevated ROS caused
the activation of AMPK-α1 in the striatum. Consistent with the above
hypothesis, we found that NAC, as well as an inhibitor (Compound
C, CC) of AMPK, reduced the elevated level of AMPKα-p172 in STHdhQ109
cells (Fig. 3E). The level of AMPKα-p172 in STHdhQ109 cells was higher
than that in STHdhQ7 cells, which was consistent with earlier reports
[39]. In addition, the elevation of the ROS level in STHdhQ109 and
STHdhQ109 by H2O2 dose-dependently increased the level of AMPKα-
p172 (Fig. 3F, Supplementary Fig. S2, respectively). These data collective-
ly support our hypothesis that ROSmightmediate, at least partially, the
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intensity of active caspases (C). At least 600 cells from each animal were counted. The data are presented as the mean± SEM. ap b 0.05, betweenWT and R6/2 mice. bp b 0.05 vs. saline-
treatedR6/2mice. Scale bars, 20 μm. (D) Rotarod performance (n= 10–12 for each condition)wasdetermined. Thedata are presented as themean±SEM. apb 0.05, betweenWTandR6/2
mice. bp b 0.05 vs. NAC-treated R6/2mice. (E) The level ofmHTT aggregates in striatal lysateswas analyzedby aﬁlter retardation assay. Insoluble aggregates thatwere retained on theﬁlters
were detected using an anti-HTT antibody. The data are presented as the mean ± SEM from three independent experiments. ap b 0.05 vs. saline-treated R6/2 mice.
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not reduce the autophosphorylation level of CaMKII, which reﬂected
the activity of CaMKII, in the striatum of R6/2 mice (SupplementaryFig. S3). Therefore, we conclude that ROS did not activate CaMKII in
the striatumof HDmice and that CaMKII was not involved in the activa-
tion of AMPK by H2O2 in striatal neurons of HD mice.
AC
D
E F
B
Fig. 3. The elevated reactive oxygen species (ROS) evoked abnormal activation of AMPK-α1 in the presence of polyQ-expandedmutant Huntingtin (HTT) in striatal cells. (A–D)Micewere
treated daily with a ROS scavenger (N-acetyl-L-cysteine, NAC; 250 mg/kg of body weight, intraperitoneal injection) or vehicle for 5 weeks from the age of 7 weeks. (A, B) Striatal lysates
were analyzed byWestern blot analyses. The results were normalized to those results of actin. The data are presented as themean± SEM from three independent experiments. ap b 0.05,
betweenWTand R6/2mice. bp b 0.05 vs. saline-treatedmice. The phosphorylation (activation) level of AMPK at Thr172 (AMPKα-p172, C) andAMPK-α1 (D) in the striatumof the indicated
animals (n=3–6 for each condition) are shown. Nuclei were stainedwith Hoechst (blue). The numbers shown in the upper-right corners of themerged images are the percentage of cells
expressing nuclear AMPKα-p172 or AMPK-α1 as indicated. Red arrows mark cells with AMPKα-p172 (C) or AMPK-α1 (D) only in nuclei. Thick arrows mark cells with AMPKα-p172 (C) or
AMPK-α1 (D) existing in cytoplasmic and nuclei. Thin arrowsmark cells expressingAMPKα-p172 (C) or AMPK-α1 (D) only in cytoplasmic regions as indicated. At least 200 cells from each
animalwere counted. Thedata are presented as themean±SEM. ap b 0.05, betweenWTandR6/2mice. bp b 0.05 vs. saline-treatedR6/2mice. Scale bars, 20 μm. (E) Cellswere treatedwith
AICAR (1 mM), NAC (5mM), or CC (10 μM) for 24 h. The data are presented as themean± SEM from three independent experiments. ap b 0.05 vs. untreated STHdhQ7 cells. bp b 0.05, vs.
AICAR-treated cells. (F) STHdhQ109 cellswere treatedwithH2O2 of the indicated concentration for 1 h. Total lysateswere assessed byWestern blot analyses. The resultswere normalized to
those results of actin. The data are presented as the mean ± SEM from three independent experiments. ap b 0.05 vs. untreated cells.
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the formation of ROS in striatal neurons
We next evaluated whether AMPK-α1 contributed to the enhanced
ROS in striatal cells. Consistent with the image analyses that are shown
in Fig. 1B the ROS level in STHdhQ109 cells was higher than that in
STHdHQ7 cells (Fig. 4A). As expected, NAC (5 mM) markedly reduced
the elevated ROS levels in both STHdHQ7 and STHdhQ109 cells. Moreover,
an AMPK inhibitor (CC) suppressed the elevated ROS levels in
STHdhQ109 cells, indicating that AMPK might regulate the elevation of
oxidative stress. Consistent with this hypothesis, the activation of
AMPKusing AICAR dose-dependently enhanced cellular oxidative stress
in STHdhQ7 and STHdhQ109 cells (Fig. 4B). Notably, a low dose of AICAR
(0.1 mM) enhanced the level of ROS only in STHdhQ109 cells but not in
the control STHdhQ7 cells, which suggests that mHTT might render
striatal neurons more susceptible to the feedback regulation between
AMPK and ROS (Fig. 4B). In addition, the exogenous expression of a
wild-type or constitutively active mutant of AMPK-α1 (AMPK-α1-
172T/D) enhanced cellular oxidative stress in STHdhQ7 and STHdhQ109
cells (Fig. 4C). Conversely, the inhibition of AMPK using CC or a domi-
nant negative mutant of AMPK (AMPK-α1-172T/A) markedly reduced
the elevated ROS levels that were evoked by H2O2 (Fig. 4C, D, E).
Consistent with the ﬁndings from STHdhQ109 cells (Figs. 3F and 4B),
primary striatal neurons harvested from R6/2 mice had higher levels
of AMPK activation and ROS than didWT striatal neurons (Fig. 5). Treat-
ment with an AMPK activator (AICAR) caused not only the activation ofED
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Fig. 4.Activation of AMPK-α1 promotedROSproduction in striatal cells. (A–E) Tomeasure cellul
NAC (5mM) and an AMPK inhibitor (compound C, CC; 10 μM) for 6 h, and incubatedwith H2D
dent experiments. ap b 0.05 speciﬁc comparison between STHdhQ7 and STHdhQ109 cells. bp b 0.05
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(C) STHdhQ7 and STHdhQ109 cells were transfected with the indicated cDNA for 48 h. The data a
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cells. bp b 0.05 vs. H2O2-treated cells. (E) Cells were transfected with the indicated construct for
three independent experiments. ap b 0.05, speciﬁc comparison between STHdhQ7 and STHdhQ1AMPK (Fig. 5A and B), but also an enhancement of ROS (Fig. 5A and C).
As was observed in Fig. 5, the elevation of ROS induced by H2O2 in the
primary striatal neurons of R6/2 mice also led to an enhanced level of
AMPK activation, which demonstrated the existence of a positive feed-
back regulation between ROS and AMPK activation. This positive loop
was also observed in other types of primary neurons (including cortical
and hippocampal neurons) collected from R6/2 mice (Supplementary
Fig. S4).
Similar to the ﬁndings obtained in striatal progenitor cells and
primary neurons, the activation of AMPK by AICAR in the striatum of
R6/2mice greatly enhanced the ROS level in the brain (Fig. 6A). In addi-
tion, the activation of AMPK in the striatum of Hdh150Q/+ mice by
intrastriatal injection of an activator of AMPK (AICAR) not only en-
hanced AMPK activation (as monitored by the expression of AMPK-α-
PT172) (Fig. 6B), but also increased the ROS level (as determined using
an in vitro ROS assay) (Fig. 6C). These observations suggest that the ac-
tivation of AMPK in the striatum of HDmice leads to an increase in ROS
levels in vivo. Taken together, our data support the hypothesis that
AMPK-α1 is not only a downstream target of ROS, but also positively
regulates ROS production in striatal neurons that express mHTT.
3.3. Positive regulation between ROS and AMPK is critical for the survival of
neurons that express mHTT
Consistent with the detrimental roles of ROS and AMPK in HDmice,
we demonstrated that blocking ROS and AMPK using NAC and CC,[H2O2] µM
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speciﬁc comparison between STHdhQ7 and STHdhQ109 cells. bp b 0.05 vs. untreated cells.
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48 h, and then treated with H2O2 for 1 h. The data are presented as themean± SEM from
09 cells. bp b 0.05 vs. WT transfected cells. cp b 0.05 vs. AMPK-172T/D transfected cells.
AB C
Fig. 5. Positive feedback regulation between reactive oxygen species (ROS) and AMPK inmutant Huntingtin (HTT)-expressing primary striatal neurons. (A–C) Cells were treated with or
without the indicated reagents (1 mM AICAR for 24 h or 100 μM H2O2 for 1 h). To measure cellular ROS levels, neuronal cells were incubated with the CellROX™ Deep Red Reagent
(red, 5 μM) for 30 min, followed by treatment with AICAR or H2O2. The levels of phosphorylation (activation) of AMPK at Thr172 (green, AMPKα-p172) in the primary striatal neurons of
the indicated animals (n=4–6 for each condition) are shown. Nuclei were stainedwith Hoechst (blue). The ﬂuorescence intensity was quantiﬁed as described in theMaterials andmethods
section. Scale bars, 20 μm.At least 50 cells fromeachanimalwere counted. The histogram shows theﬂuorescence intensity of AMPKα-p172 (B) andCellROX™Deep Red (C) in primary striatal
neurons. The data are presented as the mean ± SE from three independent experiments. ap b 0.05 between untreated WT and R6/2 mice; bp b 0.05 vs untreated R6/2 mice.
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AMPK activation (Fig. 7A, C) or elevated oxidative stress (Fig. 7B, D).
Cell survivalwas determined using theMTT (Fig. 7A, B) and the ﬂow cy-
tometric assay (Fig. 7C, D). As shown in Fig. 7A and C, a ROS scavenger
(NAC, 5 mM) blocked the death of STHdhQ109 cells that was caused by
the activation of AMPK using AICAR (1 mM). Conversely, an AMPK in-
hibitor (CC, 10 μM) protected STHdhQ109 cells from the death that was
triggered by elevated ROS (Fig. 7B, D). These observations support our
hypothesis that positive feedback regulation between the activation of
AMPK and the formation of ROS is critical for the survival of striatal neu-
rons upon stresses.4. Discussion
We previously demonstrated that AMPK-α1 is activated by a
CaMKII-mediated pathway in striatal neurons of HD and that AMPK-
α1 exerted a detrimental role in the progression of HD [21]. Because
HD is a complex disease and because AMPK has multiple upstream reg-
ulators, in the present study, we investigated whether additional path-
way(s) were involved in the regulation of AMPK-α1 in HD. Our results
indicated that the expression of mHTT in a striatal progenitor cell line
and in a transgenic mouse model of HD induces the accumulation of
ROS, which, at least partially, mediates the activation of AMPK-α1
AB C
Fig. 6. Positive feedback regulation between reactive oxygen species (ROS) and AMPK in a transgenicmousemodel (R6/2) and in a knock-inmousemodel (Hdh150Q) of HD. (A)Micewere
treated with AICAR (10 μg per mouse) or saline for 1 day at the age of 12 weeks, followed by an intravenous injection of hydroethidine (DHE, 0.5 mg per mouse). One day postinjection,
brain tissues were harvested to analyze ROS production using an IVIS spectrum imaging system. Brain images ofmice (saline-treatedWTmice (n=10), saline-treated R6/2mice (n=8),
AICAR-treated WT mice (n = 9), and AICAR-treated R6/2 mice (n = 8)) were used to determine the ROS level in the brain. The histograms show the ﬂuorescence intensity of DHE.
The pseudocolors represent photons/s/cm2/Sr. The data are presented as the mean ± SEM. ap b 0.05 between WT and R6/2 mice; bp b 0.05 vs saline-treated mice. (B, C) Mice
aged 22 months (n= 3–4 for each condition) were intrastriatally injected with AICAR (10 μg per mouse) or saline. One day postinjection, brain lysates were harvested to analyze the
expression of AMPKα-p172 (B) or DCF ﬂuorescence (C). The ﬂuorescence intensity was quantiﬁed as described in the Materials and methods section. The data are presented as the
mean ± SEM. ap b 0.05 between WT and Hdh150Q mice; bp b 0.05 vs saline-treated Hdh150Q mice.
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signaling pathways depending on the extent and duration of oxidative
stress [40], the activation of AMPK by ROS ismore commonly associated
with high levels and/or long-term oxidative stresses [41,42]. The chron-
ic treatment of HD mice with a blocker of ROS (NAC) not only reduced
the activation and nuclear enrichment of AMPK-α1 but also rescued
the levels of a survival signal (Bcl2), which was impaired by AMPK-α1
(Fig. 3). Our ﬁndings suggest that ROS is another damaging factor that
functions upstream of AMPK-α1 in HD. It has been suggested that the
initial cause of elevated ROS levels inHDpatients at early stagesmay re-
sult from the mHTT-evoked abnormal trafﬁcking of the neuronal gluta-
mate transporter, whereas, at late stages, elevated ROS levels may be
evoked by inferior mitochondrial functions [43–45].
Our data also showed that the activation of AMPK-α1 led to the in-
creased production of ROS in a striatal progenitor cell line that
expressed the full-length mHTT and in the striatum of two different
mouse models of HD (Figs. 5–6). In addition to the suppression ofCREB and Bcl2, in the present study, we showed that the overactivation
of AMPK-α1 stimulates an additional harmful pathway that enhanced
the mHTT-induced neurotoxicity. These ﬁndings suggest that positive
feedback regulation between ROS and AMPK-α1 exists in striatal neu-
rons of HD. Therefore, both NAC (an antioxidant) and CC (an inhibitor
of AMPK) were neuroprotective in striatal neurons expressing mHTT
(Figs. 2, 7). Therapeutic treatment(s) that prevent the vicious cycle be-
tween ROS formation and the activation of AMPK-α1might disrupt this
positive feedback loop and delay the progression of HD.
For HD and many other neurodegeneration diseases (including
Alzheimer's Disease, AD; Parkinson's disease, PD; and amyotrophic lat-
eral sclerosis, ALS), oxidative stress is one of the most harmful factors
that exacerbate disease progression [46–48]. The glial cell-mediated in-
crease of oxidative stress in the substantial nigra is generally believed to
affect the onset and progression of PD [49]. The major disease-causing
factor (the amyloid-β peptide) of AD is also known to induce the pro-
duction of free radicals [50], whereas chronic treatment with NAC
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AD [51]. It is believed that products of oxidative damage are usually
harmful to normal cellular functions and, thus, worsen neurodegenera-
tion. For example, 4-hydroxy-2-nonenal (4-HNE, a product of lipid per-
oxidation) suppresses the activity of the 26S proteasome [52] and, thus,
might enhance the accumulation of disease-causing mutant proteins.
Interestingly, the impairment of proteasomes further exacerbates the
generation of oxidative stress [52], which suggests that feedback regula-
tion between ROS and other harmful event(s) might be a common
mechanism in neurodegeneration. In thepresent study,we demonstrat-
ed positive feedback regulation between ROS and AMPK-α1 in the stri-
atum (Fig. 8). It is important to point out that, similar to what was
observed in STHdhQ109 cells (Figs. 3 and 4) and primary striatal neurons
(Fig. 5), a positive feedback regulationwas found in primary cortical and
hippocampal neurons (Fig. S4). An antioxidant (NAC) reduced the acti-
vation of AMPK, and an AMPK inhibitor (compound C, CC) suppressed
the elevated ROS levels in both cortical and hippocampal neurons(Fig. S4). Thus, the positive feedback regulation between ROS and
AMPK may also exist in many different types of neurons. Nonetheless,
higher levels of ROS and AMPK activation were only found in the stria-
tum of R6/2 mice (Fig. S5). Given that the striatum is particularly sensi-
tive to oxidative stress [11,53], the feedback regulation between ROS
and AMPKmight occurmainly in the striatum under normal conditions,
and may explain why the striatum is the most susceptible brain region
in HD [54].
Our ﬁndings suggest that the positive regulation between ROS for-
mation andAMPK-α1 during HDprogression is likely to occur in the cy-
toplasm of striatal cells (Figs. 1, 5 and 8). The underlyingmechanism for
such regulation is largely uncharacterized. Earlier studies suggest that
ROS may function upstream of AMPK through the activation of ATM
or through the reduction of ATP content [55–57]. In addition, a recent
report suggests that proline oxidase (POX) may mediate the regulation
between ROS generation by AMPK in cancer cells. Given the importance
of this vicious cycle in pathogenesis, further investigation concerning
mHTT ROS AMPK α1 AMPK α1-p-T172
AMPK α1-p-T172
striatal neurons
nucleus
NAC
Compound C
AMPK α1-172T/A
Neuronal cell death
Fig. 8.Apositive feedback regulation between reactive oxygen species (ROS) andAMPK activation contributes to HDprogression. In thepresent study,we demonstrate that the expression
of a polyQ-expandedmutantHuntingtin (mHTT) elevates cellular ROS in striatal cells or the striatumof a transgenicmousemodel ofHD (R6/2). Such increasedROS subsequently cause the
abnormal activation of AMPK-α1. Conversely, the activation of AMPK-α1 induces the level of cellular ROS. A scavenger of ROS (i.e.,N-acetyl-cysteine, NAC) and two inhibitors of AMPK-α1
(i.e., Compound C, AMPK-α1172T/A) reduce oxidative stresses, suppress AMPK activation, and protect striatal neurons. Collectively, the positive feedback regulation betweenAMPK-α1 and
ROS contributes to neuronal atrophy during the progression of HD.
1678 T.-C. Ju et al. / Biochimica et Biophysica Acta 1842 (2014) 1668–1680the molecular mechanism of this cycle is of great interest. Another crit-
ical aspect of such regulation is the isoform selectivity of AMPK. Our
ﬁnding that elevated oxidative stress activates AMPK-α1 in striatal neu-
rons during HD progression is consistent with previous ﬁndings in sev-
eral other cell types (e.g., rat dental pulp cells, muscle, and NIH-3T3), in
which AMPK-α1 mediates the action of ROS [26,58,59]. Nonetheless, in
some other cell types (e.g., retinal pigment epithelium cell, glioma, and
cardiomyocytes), AMPK-α2 (but not AMPK-α1) mediates the function
of oxidative stress [41,60,61]. Although these two isoforms (AMPK α1
and α2) exhibit similar catalytic activity over an artiﬁcial substrate
(SANS peptide) [62], many earlier studies suggested that AMPK-α1
and α2 are differentially regulated under different pathophysiological
conditions. In patients with type 2 diabetes, acute exercise enhances
the activity of AMPK-α2 (but not that of α1) in skeletal muscle and re-
duces the concentration of blood glucose [63]. In young non-diabetic
humans, depletions of phosphocreatine and ATP levels lead to an in-
crease of in AMPK-α2 activity in the muscle, with no signiﬁcant change
in that of AMPK-α1 [64]. It ismost likely that AMPK-α1 andα2 play dis-
tinct roles in skeletal muscles during exercise. In addition to the differ-
ences in tissue distribution and subcellular localization, the substrate
speciﬁcity of AMPK-α1 andα2may also differ greatly [65]. Here, we re-
port an important regulation of a detrimental AMPK-α1 in the striatum
of HD mice by oxidative stress. Further investigations concerning the
isoform-speciﬁc regulation of AMPK by ROS in the presence of mHTT
may greatly advance our knowledge of the role of AMPK in neurodegen-
erative diseases.
5. Conclusions
In conclusion, we demonstrate that a vicious cycle of the elevated
ROS and the activated AMPK-α1 in the striatum of HDmice contributes
to themHTT-induced neurotoxicity. The enhanced oxidative stress is an
important upstream positive regulator of AMPK-α1, which promotes
mHTT aggregation and worsens the mHTT-mediated neuronal atrophy.Chronic treatment of HD mice with a ROS scavenger (NAC) not only
reduced the activation and nuclear enrichment of AMPK-α1, but also
rescued the levels of a survival signal (Bcl2) that was impaired by
AMPK-α1. Our ﬁndings suggest that ROS and AMPK-α1 are potential
therapeutic targets for the treatment of HD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.06.012.
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